Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M
Biohaven .Biohaven .(US:BHVN) Prnewswire·2025-11-14 05:05

融资活动概述 - Biohaven Ltd 完成一项承销公开发行，以每股7.50美元的价格发行了26,833,334股普通股 [1] - 此次发行规模从原计划的1.5亿美元上调至1.75亿美元，总募集资金毛收益约为2亿美元 [1] - 增发部分包含了承销商全额行使超额配售权，额外购买了350万股普通股 [1] 资金用途 - 公司计划将此次发行的净收益用于一般公司用途 [1] 承销商信息 - 此次发行的联席账簿管理人为摩根大通、高盛、Leerink Partners、TD Cowen和Cantor [2] 公司背景 - Biohaven Ltd 是一家全球性临床阶段生物制药公司，专注于发现、开发和商业化治疗罕见病和常见病的变革性疗法 [1]

Biohaven .-Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M - Reportify